The mortality benefits identified for GLP-1 drugs present opportunities for carriers to transform how they assess metabolic risk in underwriting programs
Jones TE, Pories WJ, Houmard JA, Tanner CJ, Zheng D, Zou K, Coen PM, Goodpaster BH, Kraus WE, Dohm GL
58,59 Overall, the future research direction of GLP-1RAs involves making them more similar to those in the human body, extending their duration of action, and creating oral formulations for easier administration
Potential Compensation: Understand what types of compensation you might be eligible for, including medical expenses, lost wages, pain and suffering, and punitive damages
44 KaganV